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Abstract
During evolution, nature has embraced different strategies for species to survive. One strategy, applied by predators
as diverse as snakes, scorpions, sea anemones and cone snails, is using venom to immobilize or kill a prey. This
venom offers a unique and extensive source of chemical diversity as it is driven by the evolutionary pressure to
improve prey capture and/or to protect their species. Cone snail venom is an example of the remarkable diversity
in pharmacologically active small peptides that venoms can consist of. These venom peptides, called conopeptides,
are classified into two main groups based on the number of cysteine residues, namely disulfide-rich and
disulfide-poor conopeptides. Since disulfide-poor conotoxins are minor components of this venom cocktail, the
number of identified peptides and the characterization of these peptides is far outclassed by its cysteine-rich
equivalents. This review provides an overview of 12 families of disulfide-poor peptides identified to date as
well as the state of affairs.
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Background
Venom peptides offer a unique and extensive source of
chemical diversity as they are driven by evolutionary
pressure to improve prey capture and/or protect their
species. Among the venomous species, cone snails
can be seen as an interesting source of peptide-based
therapeutics since they produce venoms that contain
a structural and functional diversity of neurotoxins.
Cone snails as a natural source of bioactive molecules
Conus is a genus of sea snails that comprises more than
700 different species, appearing naturally in tropical and
subtropical marine waters [1]. The venom used by cone
snails is a very complex mixture consisting of more than
100 to 1000 different bioactive components and its com-
position differs from species to species. Therefore, it is
estimated that more than 700,000 different pharmaco-
logically active components can be addressed to this
genus [2, 3]. To date, only 0.2 % out of this remarkable
number of components has been functionally and struc-
turally investigated. Nevertheless, the consideration of
Conus venoms as gold mines for the discovery of new
therapeutics is validated by the knowledge that, out of
the limited number of studied conopeptides, at least
nine peptides have reached human clinical trials, and
one was approved as analgesic in 2004 [4–6].
Conopeptides are classified into two main groups based
on the number of cysteine bonds, namely disulfide-rich
and disulfide-poor conopeptides. The term “conopeptides”
is often associated with cysteine-poor peptides, while
cysteine-rich peptides are more usually recognized as
conotoxins. Conopeptides and conotoxins are both
deployed as toxic components and are likely to act in
synergy to promote a very potent effect [7]. The focus
of this review is disulfide-poor peptides, containing
none or only one disulfide bond. This group is subdi-
vided into contulakins (interacting with neurotensin
receptors), conantokins (interacting with N-methyl-D-
aspartate receptors), conorfamides (interacting with
RFamide receptor), conolysins (interacting with cellular
membranes), conopressins (interacting with vasopressin
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receptors), contryphans (interacting with CaV or KV
channels), conophans (target unknown), conomarphins
(target unknown), conomaps (target unknown), cono-
CAPs (target unknown), cono-NPYs (target unknown)
and conoGAYs (target unknown). Each of these subgroups
will be discussed in detail in the next sections.
According to Puillandre et al. [3], the so-called cysteine-
poor conopeptides seem to be closely related to cysteine-
rich conopeptides according to their signal sequences,
suggesting that a distinction based on cysteine content
and configuration is not phylogenetically relevant and
does not reflect the evolutionary history of conopeptides.
As such, some of them share highly similar signals with
known superfamilies (such as contryphan with O2 and
conomarphin with M). Two other superfamilies, B and C
for conantokins and contulakins respectively, were identi-
fied [3]. In the next sections, we will first describe cono-
peptides that have a single disulfide bond (conopressins,
contryphans, conoCAPs and conoGAYs). Subsequently,
conopeptides without cysteine residues are described.
Finally, two recently discovered hormone-like peptides
are discussed.
Conopressins
General features of conopressins
The first conopressins, conopressin-G and conopressin-S,
were described in 1987 by Cruz et al. [8]. The authors ob-
served a characteristic “scratching” effect upon intracere-
bral injection in mice, similar to that elicited by vertebrate
neurohypophyseal hormones. Conopressin-S is isolated
from Conus striatus, whereas conopressin-G is purified
from Conus geographus venom (Table 1) [8]. Later, con-
opressin-G was also found in Conus imperialis venom [9]
as well as in tissue extracts of the nonvenomous snails
Lymnaea stagnalis and Aplysia californica and the leech
Erpobdella octoculata [10–12]. γ-conopressin-vil is the
only conopressin to date including a γ-carboxyglutamate
in its amino acid structure. This γ-carboxyglutamate resi-
due mediates calcium binding which results in structural
changes of γ-conopressin-vil [13].
Vasopressin/oxytocin receptors and pharmacological
properties of conopressin T
Vasopressin (AVP, amino acid sequence CYFQNCPRG*)
and oxytocin (OT, amino acid sequence CYIQNCPLG*)
were originally identified as neurohypophysial hormones
in mammals with cyclic structures. In humans, the actions
of AVP are mediated by stimulation of tissue-specific
G-protein-coupled receptors (GPCRs) called vasopres-
sin receptors (vascular V1aR, pituitary V1bR, and renal
V2R), whereas OT acts via one OT receptor (OTR). In
mammals, vasopressin and oxytocin are multifunctional
hormones that fulfill important functions in osmoregu-
lation and endocrine control [14]. Peripherally, they
regulate water balance [15], the control of blood pres-
sure, and contraction of uterine smooth muscle and
mammary gland myoepithelium [14]. Centrally, these
peptides affect levels of aggression, depression and
bonding [16]. However, vasopressin/oxytocin-related
peptides are not restricted to vertebrates since endogen-
ous analogues have been reported in non-mammalian
vertebrates, annelids, mollusks and insects, suggesting an
old lineage for these peptides [17].
Conopressin-T, discovered by Dutertre et al. [17], be-
longs to the vasopressin-like peptide family and displays
high sequence homology to the mammalian hormone
oxytocin and to vasotocin (CYIQNCPRG*), the teleost
fish equivalent of vasopressin. Pharmacological charac-
terizations of conopressin-T across human receptors
revealed that it is a selective V1a antagonist, with partial
agonist activity at the OT receptor and no detectable
activity at V1b and V2 receptors [17]. Most peptides of
the conopressin family contain two conserved amino
acids within the exocyclic peptide (Pro7 and Gly9), which
are replaced with Leu7 and Val9 in conopressin-T. Both
amino acid positions seem to have important implications
in the binding of conopressin to its target. Whereas
conopressin-T only binds to OT and V1a receptors, an L7P
analogue had increased affinity for the V1a receptor and
weak V2 receptor binding. Looking at the NMR structures
of both conopressin-T and the L7P analogue, a difference
in the orientation of the exocyclic tripeptide was observed,
Table 1 Characteristics of conopressins. Their amino acid sequences, respective species, target, clinical potential and references are
indicated
Peptide Amino acid sequence Species Target Clinical potential Source
Lys-conopressin-G CFIRNCPKGa C. geographus vasopressin R cardiovascular/mood [8, 9]
Arg-conopressin-S CIIRNCPRGa C. striatus V1bR, OTR > V1aR [8]
γ-Conopressin-vil CLIQDCPγGa C. villepinii ? [13]
Conopressin-T CYIQNCLRVa C. tulipa V1aR, OTR [17]
Conopressin-Tx CFIRNCOP C. textile ? [68]
aN-terminal amidation; γ: gamma-carboxyglutamate; O: hydoxyproline; OTR: oxytocin-receptor; V1aR: vascular vasopressin receptor, V1bR: pituitary vasopressin receptor
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explaining the selectivity profile switch. Moreover, the
authors observed that when Gly9 was replaced with Val9
in OT and AVP, the peptides’ activity was converted from
agonist to antagonist, revealing this position as an agonist/
antagonist switch at the V1a receptor [17].
Biological role in the venom
The existence of homologues of the vasopressin/oxyto-
cin family of peptides in cone snail venom is thought to
be a result of evolution from pre-existing endogenous
snail peptides [8, 18]. As such, it is suggested that these
peptides have been continuously used in nervous sys-
tems but have evolved opportunistically for specialized
functions [8]. An example is conopressin-T. This pep-
tide has seven out of nine residues identical to teleost
fish vasotocin (AVT), including the disulfide containing
ring. Since C. tulipa preys on fish, it is very likely that
conopressin-T specifically targets teleost AVT recep-
tors [17]. The presence of vasopressin/oxytocin-related
peptides in invertebrates is thought to be a duplication
of an ancestral gene that occurred before the diver-
gence of vertebrates and invertebrates over 600 million
years ago [19].
Contryphans
General features of contryphans
The first D-amino acid containing conotoxin, contryphan-
R, was purified from Conus radiatus [20]. Most of the
contryphans share the conserved sequence motif,
CO(D-W or D-L)XPWC*, that includes a tryptophan or
leucine in the D-configuration, a disulfide bond between
the two cysteines, C-terminal amidation and in most cases
hydroxylation of a proline residue preceding the D-Trp
residue [21]. The N-terminal Cys-Pro/Hyp peptide bond
exhibits cis-trans isomerization, but the more abundant
cis isomer is believed to be the functionally relevant con-
former. The contryphan motif is a robust structural scaf-
fold that maintains the backbone structure independent of
the amino acid that is substituted at residue X. This resi-
due is Gln in contryphan-Sm, Glu in contryphan-R, and
Lys in contryphan-Vn (Table 2) [22]. The bromination of
Trp7 in contryphan-R yields L-6-bromotryptophan [21].
Mediated by their disulfide bond, contryphans are cyclic
peptides and thus provide an interesting scaffold for
molecular design [23].
With the discovery of bromocontryphan and the iden-
tification of an encoding cDNA for a precursor, Jimenez
et al. [21] suggested that three related peptides are gen-
erated in C. radiates venom ducts through the pathway
in Fig. 1 [21].
Pharmacological properties of contryphans
Contryphan-Vn (Fig. 2) is a D-Trp-containing contryphan
isolated from Conus ventricosus that has a positively
charged Lys residue within the intercysteine loop [24].
This intercysteine basic residue, Lys6 participates in a
strong salt bridge with Asp2. By performing electro-
physiological experiments on insect neurosecretory
cells as well as in rat chromaffin cells, Massilia et al.
[24] identified contryphan-Vn as a weak voltage-gated
and Ca2+-dependent K+ channel modulator (> 10 μM).
However, despite this weak response, it is unlikely that
Table 2 Characteristics of contryphans. Their amino acid sequences, respective species, observed activity and references are
indicated
Peptide Amino acid sequence Species Activity Source
Contryphan-R GCOWEPWCa C. radiatus “Stiff-tail” syndrome in mice [20]
[des-Gly1]contryphan COWEPWCa C. radiatus “Stiff-tail” syndrome in mice [20]
Bromocontryphan-R GCOWEPW+Ca C. radiatus “Stiff-tail” syndrome in mice [21]
Contryphan-Sm GCOWQPWCa C. stercusmuscarum “Stiff-tail” syndrome in Webster mice [69]
Contryphan-P GCOWDPWCa C. purpurascens “Stiff-tail” syndrome in Swiss Webster mice/inhibits HVA Ca2+ channels [69]
Leu-contryphan-P GCVLLPWC C. purpurascens Body tremor and mucous secretion in fish [70]
Contryphan-Tx GCOWQPYCa C. textile “Stiff-tail” syndrome and paralysis of extremities in Swiss Webster mice [71]
Leu-contryphan-Tx CVLYPWC C. textile Folding and drooping of dorsal fins and passivity in Siamese fighting fish [71]
Contryphan-Vn GDCPWKPWCa C. ventricosus ? (VGPC, Ca2+ dependent) [24, 72]
Glacontryphan-M NγSγCPWHPWCa C. marmoreus Inhibits L-type VGCC [22, 73]
Am975 GCPWDPWCa C. amadis Inhibits HVA Ca2+ channels [25]
Lo959 GCOWDPWCa C. loroisii Activates HVA Ca2+ channels [25]
Contryphan-fia GCODWQPWC C. figulinus ? [74]
[W8S]contryphan-Vn GDCPWKPSCa C. ventricosus ? [75]
Contryphan-fib GCOWMPWCa C. figulinus ? [76]
aC-terminal amidation; W+: 6-L-bromotryptophan; O: hydroxyproline; W: D-tryptophan; L: D-leucine; γ: gamma-carboxyglutamate; VGPC: voltage-gated potassium
channel, VGCC: voltage-gated calcium channel, HVA: high voltage-activated
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potassium channels are the real targets of contryphan-Vn.
Also, binding experiments carried out on membrane
preparations of transformed HEK 293 cells overexpress-
ing human VGPC, KV1.1 and KV1.2 did not evidence a
competition of contryphan-Vn for the BgK (sea anem-
one neurotoxin) binding site [24].
Glacontryphan-M is a contryphan purified from Conus
marmoreus venom that contains Gla (γ-carboxyglutamic
acid) residues [22]. These Gla residues hold a malonate-
like side chain which can chelate divalent metal ions. As
such, the binding of calcium ions to glacontryphan-M
induces perturbations of the N-terminal residues Gla2,
Ser3and Gla4, and the Cys11-Cys5-Pro6 region of the
intercysteine loop, resulting in an increased exposure
and slight reorientation of the stacked aromatic rings of
His8 and D-Trp7 relative to the positioning of Trp10.
Biological role in the venom
The biological activity of contryphans is that of causing
a “stiff-tail” syndrome in mice when injected intracrani-
ally or triggering body tremor and mucous secretion
when injected intramuscularly into fish [22]. At higher
doses, contryphan-R induces more generalized excitatory
effects in mice such as barrel rolling and seizures [20].
The first identification of a functional target for a con-
tryphan was for contryphan-Vn from Conus ventricosus,
which affects both voltage-gated and Ca2+-dependent
potassium channels [22]. Later, glacontryphan-M was
identified as a calcium-dependent antagonist of L-type
voltage-gated Ca2+ channels (VGCC) expressed in mouse
pancreatic β-cells.
The structural investigation of glacontryphan-M sug-
gests that the function of Gla in VGCC blockage by
glacontryphan-M is one of the following [22]:
1. To modify the structure of glacontryphan-M so
that functional determinants interact with the
channel.
2. To enable glacontryphan-M to bind to the membrane
surface. The Gla residues facilitate the interaction with
specific calcium channel sites via bridging of calcium
and membrane components.
Fig. 1 Pathway of contryphan formation. It is presumed that bromination precedes the final proteolytic cleavage. The presence of two
non-brominated forms, contryphan and [des-Gly1]contryphan, in native venom may be due to incomplete post-translational processing with
the [des-Gly1]analog arising from a non-physiological post-mortem proteolysis. Reprinted with permission from Jimenez et al. [21]. Copyright
by the American Chemical Society (1997)
Fig. 2 Three-dimensional representation of contryphan-Vn indicating amino acids and disulfide bond (left) and mesh structure (right). Figures
were created with Pymol [82] (PDB 1N3V)
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3. To ensure a localized enrichment of calcium ions
at the channel opening which facilitates a change
in the structure of the channel. This allows
glacontryphan-M to bind to an antagonist-binding
site with higher affinity.
Other contryphans targeting Ca2+ channels are Lo959
an Am975 (Table 2), identified in the venom glands of
Conus loroisii and Conus amadis, respectively. Both Lo959
and Am975, which differ only in one posttranslational
modified residue, target high voltage-activated Ca2+ chan-
nels. Intriguingly, while Lo959 increases the Ca2+ current,
Am975 causes inhibition of VGCC [25].
ConoCAPs
General features of conoCAPs
ConoCAPs or cardioactive peptides from cone snails are
described by Möller et al. [26]. The conoCAPs (a, b, c,
Table 3) reported in this work have up to 78 % of se-
quence homology with crustacean cardioactive peptides
(CCAP, amino acid sequence PFCNAFTGC*). The dis-
covery of conoCAPs in cone snail venom emphasizes
the significance of their gene plasticity to have mutations
as an adaptive evolution in terms of structure, cellular
site of expression, and physiological function.
Contrary to CCAP, conoCAP-a decreases heart rate
(HR) and blood pressure in rats. These effects are in ac-
cordance with the reduced systolic calcium amplitude
and contraction recorded in single ventricular myocytes
from rat hearts. Moreover, analogs of conoCAP-a were
used to determine structure-function relationships. The
reduction in HR was lost when the Cys residues were
substituted by Ala or when they were S-methylated. On
the other hand, less significant changes were observed
when intracystine amino acids were replaced by Ala [26].
Pharmacological properties of conoCAPs
When conoCAP-a was applied on rat cardiac myocytes,
the amplitude of systolic [Ca2+]i and contractile activity
gradually decreased. Therefore, it was expected that
conoCAP-a would affect L-type Ca2+ channel (LTCC)
current since systolic Ca2+ transient in cardiac muscle is
triggered by Ca2+ entry via these channels. However,
voltage-clamp experiments measuring LTCC showed
that conoCAP-a had no effect on LTCC current, ruling
out LTCC as a target of the peptide. Likewise, conoCAP-a
did not affect other cell membrane channels and mem-
brane receptors involved in the cardiovascular physiology.
Further studies are needed to indicate the specific target
of conoCAP-a.
ConoGAYs
General features of conoGAYs
ConoGAYs are a new class of disulfide-poor conotoxins
with one disulfide bond, recently found in the venom
gland of Conus australis. The name conoGAY originates
from the first three amino acids of the peptide AusB
(Table 4). Contrary to most disulfide-poor conotoxins,
no post-translational modifications were observed in
AusB. The authors investigated the effect of conoGAY-
AusB on a large panel of ion channels. As such, the pep-
tide was electrophysiologically screened against a panel
of NaVs, KVs and nAChRs as expressed heterologously in
Xenopus laevis oocytes. In addition, a broad screening
was performed against a collection of microorganisms
(29 gram-negative bacteria, ten gram-positive bacteria
and two yeast strains) [84]. Unfortunately, the real target
of this peptide remains to be revealed.
Conantokins
General features of conantokins
Conantokins are a class of conopeptides (17–27 amino
acids) without cysteine residues that selectively influence
NMDA (N-methyl-D-aspartate) receptors (Table 5) [4,
27]. Conantokin-G (Con-G) from Conus geographus was
introduced in 1984 as “the sleeper peptide”, because it
induces a sleep-like state in mice when injected intrace-
rebrally [28]. Similarly, conantokin-T from Conus tulipa,
discovered by Haack et al. [29], induces sleep-like symp-
toms in young mice (10–13 days old); however, these
manifestations are of smaller duration than those pro-
duced by Con-G. On account of these sleep-like symp-
toms, the conopeptides were named after the Philippino
word for sleepy, antokin, resulting in “conantokin” [30].
Curiously, in mice older than three weeks, the same
peptides induce hyperactive behavior which is more
dramatic for Con-T than for Con-G [29, 31]. Later it
was shown that both Con-G and Con-T interact with
NMDA receptors in an antagonistic way [30, 32], pro-
duced by a competitive antagonism at the glutamate
binding site of the NMDA receptor [27].
Conantokins show a disproportionately large number
of acid labile post-translational γ-carboxyglutamic acid
(Gla) residues. These Gla residues play a critical role in
the chelation of divalent cations, which causes a
stabilization of the α-helical secondary structure of the
conantokins [27]. As such, conantokin-G requires the
presence of divalent cations to form a stable α-helix,
while conantokin-T adopts a stable structure, both in the
Table 3 Characteristics of conoCAPs. Their amino acid sequences,
respective species and references are indicated
Peptide Amino acid sequence Species Target Source
ConoCAP-a PFCNSFGCYNa C. villepinii ? [26]
ConoCAP-b VFCNGFTGCGa C. villepinii ? [26]
ConoCAP-c LFCNGYGGCRGa C. villepinii ? [26]
aC-terminal amidation
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presence or absence of divalent cations. However, binding
of divalent cations increases the α-helical content of both
peptides [27]. Moreover, the first five amino acids of con-
antokins, especially Glu2 and Gla4 and a hydrophobic resi-
due at position 12 are critical for functional activity in
vitro. Position 5 appears to be important in determining
the NMDA receptor subtype selectivity profile of the
conantokins [27]. For Con-G and Con-T, in particular,
Gla3 and Gla4 have shown to play an important role in
the activity of these peptides [32]. Figure 3 shows the
three-dimensional structures of Con-T and Con-G.
NMDA receptors and pharmacological properties of
conantokins
The NMDA receptor is a heterooligomeric ligand-gated
ion channel mediating excitatory synaptic transmission.
The channel has multiple allosterically coupled recogni-
tion sites for different components such as glutamate,
glycine, polyamines, ions and use-dependent channel
blockers. It is a specific type of ionotropic glutamate
receptor, because the agonist molecule NMDA (N-me-
thyl-D-aspartate) binds selectively to this receptor and
not to other glutamate receptors. At resting membrane
potential, NMDA receptors are blocked by Mg2+. The
activation of NMDA receptors depends on two actions:
binding of agonist (such as NMDA) and relief of
voltage-dependent channel blockade by Mg2+, which
happens upon postsynaptic depolarization. As a conse-
quence, NMDA receptors become highly permeable to
Ca2+ which can influence gene activation, neuronal
survival, axon outgrowth and synaptic strength [33].
Native NMDA receptors are composed of subunits
from three families, NR1, NR2 and NR3. A single gene
encodes the NR1 family, which consists of eight known
splice variants. Four different genes encode the mem-
bers of the NR2 family (NR2A, NR2B, NR2C and
NR2D). This latter family is shown to be the target of
most conantokins identified up to now.
Conantokins also interact with NMDA receptors of
distinct subunit composition. As such, conantokin-G
from Conus geographus potently inhibits NMDA-evoked
currents in Xenopus oocytes expressing NR1/NR2B
heteromeric receptors [34]. In contrast, conantokin-R
potently blocks NMDA-evoked currents in Xenopus
oocytes expressing NR1/NR2A and NR1/NR2B hetero-
meric receptors [35].
Biological role in the venom
The question rises why cone snails have a peptide that
functions as a NMDA or Glu antagonist in their venom?
When Con-G is injected intramuscularly in fish, a jerky
and uncoordinated swimming occurs, which may slow
down the fish’s escape. As an alternative, the peptide
may act together with other conopeptides to aid in the
Table 5 Characteristics of conantokins. Their amino acid sequences, respective species, target, clinical potential and references are
indicated
Peptide Amino acid sequence Species Target Clinical potential Source
Conantokin-G GEyyLQyNQyLIRyKSNa C. geographus NR2B > NR2C, NR2D pain/epilepsy [28, 77]
Con-T GEyyYQKMLyNLRyAEVKKNAa C. tulipa NR2B, NR2A [29]
Con-R GEyyVAKMAAyLARyNIAKGCKVNCYPa C. radiatus NR2B, NR2A [35]
Con-L GEyyVAKMAAyLARyDAVNa C. lynceus ? [78]
Con-Ca2 GYγγRγIAγTVRγLEEA C. caracteristicus ? [79]
Con-Gm GAKyRNNAyAVRyRLEEI C. gloriamaris ? [79]
Con-Qu GYγγRγVAγTVRγLDAA C. quercinus ? [79]
Con-Oc GEγγRKAMAγLEAKKAQγALKA C. orchroleucus ? [79]
Con-Pr1 GEDγYAγGIRγYQLIHGKI C. parius NR2B, NR2D [80]
Con-Pr2 DEOγYAγAIRγYQLLKYGKI C. parius NR2B < NR2D [80]
Con-Pr3 GEOγVAKWAγGLRγKAASNa C. parius NR2B, NR2D [80]
Con-E GEγγHSKYQγCLRγIRVNNVQQγC C. ermineus ? [77]
Con-P GEγγHSKYQγCLRγIRVNKVQQγC C. purpurascens NR2B, NR2A [77]
Con-Br GDγγYSKFIγRERγAGRLDLSKFP C. sulcatus (brettinghami) NR2B, NR2D, NR2A < NR2C [81]
aN-terminal amidation; Gla: γ-carboxyglutamic acid; NR2: NMDA receptor
Table 4 Characteristics of conoGAY-AusB. Its amino acid sequence, respective species and reference are indicated
Peptide Amino acid sequence Species Target Source
ConoGAY-AusB GAYFDGFDVPCVPRRDDC C. australis ? Unpublished data, [84]
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hunting strategy of the snail. As such, conantokin-G is a
component of the nirvana cabal, a synergistic effect
caused by different conotoxins, which brings the prey in
a relaxed and sedated state. Contulakin-G assists in this
nirvana cabal. Another possibility is that some compo-
nents of the venom are reserved for defensive processes.
Since Glu is a neurotransmitter at the invertebrate
neuromuscular junction, injection of a potent glutamate
antagonist into an invertebrate predator causing the in-
hibition of signal transmission, may be a very effective
defense strategy [30].
Clinical potential of conantokins
Over-activation of NMDA receptors has been implicated
in a variety of neurological disorders including chronic
pain, epilepsy, ischemic stroke and neurodegenerative
disorders such as Parkinson’s disease and Alzheimer’s
disease. Clinical and preclinical studies have demon-
strated that antagonists of NMDA receptors may be
useful in treating these neurological disorders. Unfortu-
nately, the side effect profiles of many NMDA antago-
nists (which include psychotomimetic, amnesic and
motor-impairing actions and neurotoxicity) limit their
usefulness in humans [36, 37].
Conantokins, however, represent a class of NMDA an-
tagonists with an improved safety profile as the following
examples illustrate [27]. First, intrathecal delivery of con-
antokins produces a potent antiallodynic effect in
models of tissue or nerve injury induced pain at doses
well below those associated with motor impairment.
Moreover, it was observed that this antinociceptive effect
of conantokin-G only affects the component of pain be-
havior that involves alterations of nociceptive processing
secondary to persistent injury and central sensitization.
In contrast, at doses that did not interfere with motor
function, conantokins had no effect on “acute” nocicep-
tive responses produced by thermal or chemical stimula-
tion. Therefore, the analgesic properties of conantokins
are superior in relation to non-subtype selective NMDA
antagonists. Second, conantokins display a broad anti-
convulsant profile in experimental seizure models with a
large separation between effective and toxic doses in
comparison with other classes of NMDA antagonist
drugs. Finally, conantokins may represent an important
therapeutic tool in the treatment of ischemic stroke, and
should theoretically be effective in hemorrhagic stroke
where current “clot-busting” drugs are contraindicated.
Con-G and Con-T appear equipotent in antinocicep-
tive and anticonvulsant tests, but Con-G is effective in
anti-parkinsonian models while Con-T is not. Neverthe-
less, the potential pharmacological selectivity of conan-
tokins, coupled with their in vivo efficacy and favorable
safety profiles, indicates that these peptides represent an
important class of compounds for further evaluation as
human therapeutics. As such, CGX-1007, the synthetic
variant of conantokin-G, is going through clinical test
phases to treat epilepsy [38] (also reviewed in [27, 39–41]).
A disadvantage of conantokins is their poor bioavailability,
which would require their direct delivery into the central
nervous system (intrathecally for instance) [27].
Fig. 3 Three-dimensional representation of (a) Con-T and (b) Con-G, indicating amino acids (left) and mesh structure (right). CGU = Gla: γ-
carboxyglutamic acid. Conantokins adopt an α-helical solution structure in the presence of divalent cations in which charged carboxyl groups
of the Gla residues are positioned along one face of the helix and hydrophobic residues are on the opposite face [83]. Figures were created
with Pymol [82] (PDB 1ONT and 1ONU for Con-T and Con-G, respectively)
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Contulakin
General features of contulakin-G
Contulakin-G was discovered in the venom gland of the
fish hunting cone snail Conus geographus by Craig et al.
[18]. An interesting feature of contulakin-G is the glycosyl-
ated Thr10 (Table 6). Moreover, the C-terminal sequence
of contulakin-G shares similarity with an endogenous
neurotensin found in vertebrate animals [42]. Conse-
quently, both glycosylated and non-glycosylated analogs of
contulakin-G revealed to be potent agonists of rat neuro-
tensin receptor type 1. However, the glycosylated analog is
ten-fold more active than the non-glycosylated form. The
role of the glycan was first assumed to increase the stabil-
ity of contulakin-G or to facilitate its transport to the site
of action [18]. Later, Lee et al. (2015) found that both
glycosylation and charged amino acid residues contrib-
ute to the neurotensin receptor desensitization proper-
ties of contulakin-G and neurotensin [42].
Neurotensin receptors and pharmacological properties of
contulakin-G
Three neurotensin receptors have been identified so far
(NTSR1-3), from which both NTSR1 and NTSR2 are G-
protein-coupled receptors. Neurotensin (NTS, amino acid
sequence ZLYENLPRRPYIL) is a 13-amino-acid peptide that
functions both as neurotransmitter and hormone through
the activation of NTSR1. This peptide modulates the activity
of dopaminergic systems in the brain, but also modulates
opioid-independent analgesia and the inhibition of food in-
take, whereas in the gut, NTS regulates a range of digestive
processes [43]. Neurotensin receptors have been studied as
molecular targets for the treatment of pain, schizophrenia,
addiction or cancer [27]. White et al. [43] determined the
crystal structure of Rattus norvegicus NTSR1, providing a
modeling tool for drug discovery. Recently, Lee et al. [42]
used this model in the context of investigating the
desensitization properties of both neurotensin and
contulakin-G. Compared to neurotensin, contulakin-G is a
weaker agonist exhibiting significantly lower desensitization
potency. As such, these structure-activity relationship and
computer modeling studies suggest that replacements of the
charged and glycoamino acid residues in contulakin-G may
lead to systemically active NTS analogs with diverse potencies
for activating and desensitizing neurotensin receptors [42].
Biological role in the venom
Looking at the role that contulakin-G might have in
capturing fish by C. geographus, the peptide is believed
to suppress the sensory circuitry in the prey. As C. geo-
graphus is a net hunter, contulakin-G may be part of
eliciting a sedated state in the fish prey [44].
Clinical potential of contulakin-G
Contulakin-G is a potent analgesic in a number of pain
models such as tail-flick (acute pain), formalin test, and
CFA-induced allodynia inflammatory pain [18]. More-
over, its synthetic analog, named CGX-1160, reached a
clinical development stage for the treatment of chronic
intractable pain following intrathecal administration in
patients with spinal cord injury [42] (also reviewed in
[27, 39–41]). However, when epidural delivery was per-
formed, CGX-1160 was considerably less potent sug-
gesting its restricted ability to diffuse through the
meningeal barrier [44].
Conorfamides
General features of conorfamides
The first conorfamide, CNF-Sr1 from C. spurius, was
characterized by Maillo et al. [45] (Table 7). Conorfamide-
Sr1 belongs to the RFamide neuropeptide family and was
the first RFamide peptide to be found in any venom. The
peptide was shown to cause hyperactivity in mice older
than 16 days. Another FMRFamide-related peptide (FaRP)
is conorfamide-Sr2, described by Aguilar et al. [46].
CNF-Sr2 also produces hyperactivity when injected
intracranially into mice and demonstrated other symp-
toms such as paralysis in snails and limpet [46]. A third
conorfamide, Vc1 from C. victoriae, showed bioactivity
upon injection in mice and calcium imaging of mouse
dorsal root ganglion cells revealed that the peptide
elicits an increase in intracellular calcium levels [47].
Table 6 Characteristics of contulakin-G. Its amino acid sequence, respective species, target, clinical potential and reference are indicated
Peptide Amino acid sequence Species Target Clinical potential Source
Contulakin-G ZSEEGGSNAT#KKPYIL C. geographus Neurotensinreceptor Pain [18]
Z = pE: pyroglutamate; T#: [β-D-Gal-(1→ 3)-α-D-GalNAc-(1→)]Thr
Table 7 Characteristics of conorfamides. Their amino acid sequences, respective species, targets and references are indicated
Peptide Amino acid sequence Species Target Source
Conorfamide-Sr1 GPMGWVPVFYRF* C. spurius RFamide receptor? [45]
Conorfamide-Sr2 GPMγDPMγIIRI* C. spurius ? [46]
Conorfamide-Vc1 HSGFLLAWSGPRNRFVRF* C. victoriae ? [47]
*C-terminal amidation
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RFamide receptors and pharmacological properties of
conorfamides
The prototypical RFamide neuropeptide is the tetra-
peptide Phe–Met–Arg–Phe–NH2 (FMRFamide) that
was purified from the clam Macrocallista nimbosa on
account of its cardioexcitatory activity. In general, RFa-
mide peptides represent a family of regulatory peptides
that possess the Arg-Phe-NH2 motif at their C-
terminus. In mammals, seven RFamide peptides have
been characterized [48]. The RFamide distribution pat-
terns appear to be limited to specific brain areas where
they are involved in essential functions such as cardio-
vascular regulation, pain modulation, weight control
and food consumption [47, 49].
Several G-protein coupled receptors (GPCRs) have
now been identified as receptors for the mammalian
RFamide peptides. These include the neuropeptide FF
receptors 1 and 2 (NPFF1R and NPFF2R), the pyrogluta-
mylated RFamide peptide receptor (QRFPR), the kiss-
peptin receptor and the prolactin-releasing peptide re-
ceptor (PrRPR). Each of them is implicated in a series of
biological events. As such, NPFF1R is localized in the
human hypothalamus and surrounding areas supporting
the idea that RFamide peptides play a role in central co-
ordination of neuroendocrine and autonomic responses
in humans [49]. Next, since QRFP, interacting with
QRFPR, is expressed in regions of the hypothalamus
involved in control of feeding behavior, this peptide and
its receptor are involved in the increasing intake of a
high fat diet. Other members of the RFamide family may
play roles in the reproductive tract (kisspeptin receptor),
or regulate hormone secretion (PrRPR) [50]. Up to now,
the specific receptor(s) of the described conorfamides
have not yet been discovered.
Biological role in the venom
In invertebrate nervous systems, the peptides of the RFa-
mide family have a host of diverse functions such as
modulation of muscle contraction, control of locomotor
activity, regulation of water balance, cardioexcitatory
activities and neuromodulatory activities. The RFamide
motif appears to be both an ancient and a convergent
feature of neuropeptide evolutions [51].
Conophans
General features of conophans
Pisarewicz et al. [52] presented four interesting disulfide-
poor conopeptides not only incorporating D-amino acids
into their sequences, but also hydroxyvaline. The pep-
tides containing D-Val were termed conophans while
the peptides with γ-hydroxyvaline were named γ-
hydroxyconophans (Table 8). Conophans are not the only
conopeptides including D-amino acids, other examples are
contryphan-R [20], conomap-Vt [53] and conomarphin
[54]. The latter two will be discussed in the following
sections. contryphans were discussed earlier.
The modification of polypeptide chains by epimeriza-
tion of standard L-amino acids to produce their D-coun-
terparts is rarely observed [52]. Nevertheless, the
modification of L- to D-amino acids in the spider venom
component ω-agatoxin IVB showed to increase stability
and potency. As such, D-Ser46 of ω-agatoxin IVB pro-
vides more resistance to the major venom protease and
is a more potent blocker of the P-type voltage-sensitive
calcium channels than its L-ser46 counterpart [55]. The
observation of a γ-hydroxylation of non-Pro amino acids
is even rarer than epimerization. The reason why this
event is uncommon is that a hydroxyl group in the γ-
position of any amino acid (except Pro) could undergo
nucleophilic attack to form a stable five-membered lac-
tone ring. Therefore, the presence of γ-D-hydroxyvaline
is unexpected. It is hypothesized that the structural
motif found in γ-hydroxyconophans, Ser-D-Hyv-Trp, is
stabilized by specific interactions between the D-amino
acid and its neighboring L-counterparts while these in-
teractions inhibit lactonization [52]. Up to now, the tar-
get of conophans remains to be revealed.
Conomap
General features of conomap-Vt
Conomap-Vt (Conp-Vt) is an unusual linear tetradecapep-
tide isolated from Conus vitulinus venom. Its sequence
Table 8 Characteristics of conophans. Their amino acid sequences, respective species and references are indicated
Peptide Amino acid sequence Species Target Source
Conophan gld-V
γ–hydroxyconophan gld-V*
AOANSVWS
AOANSV*WS
C. gladiator ? [52]
Conophan mus-V
γ–hydroxyconophan mus-V*
SOANSVWS
SOANSV*WS
C. mus ? [52]
O hydroxyproline; V: D-Valine; V*: D- γ-hydroxyvaline
Table 9 Characteristics of conomap-Vt. Its amino acid sequence, respective species, target and reference are indicated
Peptide Amino acid sequence Species Target Source
Conomap-Vt AFVKGSAQRVAHGYa C. vitulinus ? [excitatory peptide] [53]
aN-terminal amidation; F D-type phenylalanine
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displays significant homology (≤ 65 %) to peptides of the
MATP (myoactive tetradecapeptide) family, which are im-
portant endogenous neuromodulators in mollusks, anne-
lids and insects. Conomap-Vt contains a D-phenylalanine
at position 2 that was suggested to have evolved for prey
capture, since isomerization of L-Phe enhanced biological
activity of this conopeptide (Table 9) [53].
Pharmacological properties of conomap-Vt
Since peptides belonging to the MATP family cause exci-
tatory effects [56, 57], Conp-Vt was tested for excitatory
activity in several mollusk isolated tissue preparations
such as buccal mass, crop, penis retractor muscle and foot
[53]. The initial concentration of Conp-Vt (10 nM) pro-
duced a contraction or enhanced existing spontaneous
contractions in all tissues except the foot. Further investi-
gations indicated that Conp-Vt has a potent excitatory
effect, particularly on the buccal mass that was showed by
its EC50 of 8 nM [53]. Moreover, Conp-Vt was tested for its
ability to induce tachyphylaxis, which is described as the acute
loss of response upon repeated stimulations with agonists
[58]. Similar to acetylcholine (ACh), repeated doses of Conp-
Vt were tachyphylactic. However, it appears that Conp-Vt
contractions were non-cholinergic in origin. Finally, the
authors concluded that Conp-Vt acts at non-cholinergic
receptors to cause the release of ACh and contraction [53].
Biological role in the venom
Conp-Vt is a major component of the venom of C. vitu-
linus. Therefore, it is suggested that this peptide may
play an important role in prey capture. Indeed, a peptide
such as Conp-Vt might disrupt muscle contraction,
which is an efficient weapon in prey subjugation and
capture. However, the function of Conp-Vt is limited to
skeletal musculature, since cardiac muscle response was
not affected in vertebrates. The authors propose that
Conp-Vt has evolved from the cone snail’s own en-
dogenous MATP peptide for specialized venom use [53].
Conomarphins
General features of conomarphin
Conomarphin was discovered in 2008 by Han et al. [54].
The cDNA-encoded precursor of conomarphin shares
the conserved signal peptide with peptides from the
M-superfamily, but the amino acid sequence of this
peptide totally differs from other members of this
superfamily. Conomarphin is namely a cysteine-free
and D-amino acid containing conotoxin purified from
the venom of Conus marmoreus. Moreover, it has a
proline residue at position 8, but a hydroxylated
proline at position 10 (Table 10) [54].
The three-dimensional structure of conomarphin dis-
plays a 310 helix at the C-terminus and a Pro8-centered
compact loop region (Fig. 4). The authors suggested that
D-Phe13 is essential for the structure of conomarphin,
since no loop could be found in L-Phe13-conomarphin.
Huang and Du [59] investigated the influence of the
hydroxyproline at position 10 of conomarphin. This pro-
line hydroxylation occurs with high specificity, since
only one of both proline residues is hydroxylated. The
authors found that in a Hyp10Pro variant, a type-II β-
turn is formed between residues 11 and 14 instead of a
Table 10 Characteristics of conomarphins. Their amino acid
sequences, respective species and references are indicated
Peptide Amino acid sequence Species Target Source
Conomarphin DWEYHAHPKONSFWT C. marmoreus ? [54]
Conomarphin-14 DWEYHAHPKONSFW C. marmoreus ? [60]
Conomarphin-8 HPKONSFW C. marmoreus ? [60]
O: hydroxyproline; F: D-type phenylalanine
Fig. 4 Three-dimensional representation of conomarphin indicating amino acids (a) and mesh structure (b). Figures were created with Pymol [82]
(PDB 2YYF)
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310 helix at the C-terminus of native conomarphin.
Thus, the lack of a hydroxyl group changes the electric
charge distribution and induces the loss of a hydrogen
bond between Pro10 and D-Phe. This might not only
have an impact on the conformation of conomarphin,
but also the physiological function [59].
Conomarphin-14 and conomarphin-8 are two variants
of conomarphin that were extracted from the venom of
C. marmoreus by thiol-exchange chromatography and
RP-HPLC. Compared to conomarphin, conomarphin-
14 misses the C-terminal Thr15 residue and in
conomarphin-8, a cleavage between Ala6 and His7 of con-
omarphin seems to have occurred. Zhang et al. [60] sug-
gested that both conomarphin-8 and conomarphin-14
might have similar structures, because the removed parts
are not involved in the formation of conomarphin’s struc-
tural elements (310 helix and centered loop).
Conomarphin-8 shares significant sequence similarity
with the conophans, which implies that the identification
of conomarphin-8 is not an artifact. Consequently, the au-
thors raise some intriguing questions: “Is it possible that
these short peptides like conomarphin-8 and conophans
are actually the final products, and that conomarphin and
conomarphin-14 are only intermediates of the maturation
process of conomarphin-8? Or do both conomarphin-8
and conomarphin have their separate biological func-
tions?” These points certainly need further investigation.
Conolysins
General features of conolysins
Conolysins are conopeptides that have the ability to
disrupt the integrity of cell membranes. The first cono-
peptide shown to have this cytolytic activity was
conolysin-Mt from Conus mustelinus (Table 11). Cyto-
lytic peptides are among the largest group of toxins
produced by living organisms, which include bacteria,
viruses, insects, marine invertebrates and reptiles [61].
Pharmacological properties of conolysins
When conolysin-Mt is intracranially injected into 16-
day-old Swiss-Webster mice, a backward shuffling, like a
moonwalk, is observed. When the mouse touches an
obstacle during a moonwalk, it jumps in the air and
often goes into a seizure. Therefore, these peptides are
named “moonwalker peptides”. Both conolysin-Mt1 and
Mt2 were found in the venom of C. mustelinus. The
least abundant of the two peptides (Mt1) was more ac-
tive in this moonwalker assay, causing the full moon-
walker phenotype to be observed within 35 min using
roughly 3 nmol. Mt2 elicited the phenotype in 150 min,
using roughly 12 nmol. To reveal the peptides’ target,
synthetic Mt1 was tested on Xenopus oocytes showing
a collapsed membrane potential within seconds. Within
minutes, visible holes in the oocytes were observed, re-
vealing this toxin as a cytolytic toxin. Moreover, the
peptide was tested against three bacterial strains: E. coli
D21, E. coli ATCC 25922, and S. aureus ATCC 6538. It
exhibited low antibacterial activity against the two E.
coli strains tested, with the minimal inhibitory concen-
tration (MIC) > 50 μM. The MIC against the gram-
positive S. aureus was 25–50 μM. To explain the low
antibacterial activity of conolysin-Mt, it was suggested
that larger aggregates might fail to pass the outer bar-
rier of bacteria. In agreement, the lower MIC-values for
S. aureus suggest that the peptide is more active against
gram-positive rather than gram-negative bacteria, as
the latter has an additional outer membrane. To put
things in perspective, melittin – the main peptide in
Apis melifera (honey bee) venom – exhibits potent anti-
bacterial activity on both gram-negative and gram-
positive bacteria. Its antibacterial activity under the
same assay condition is 1–20 μM, depending on the
bacterial strain used [61].
Cono-NPYs
General features of cono-NPYs
Wu et al. [62] described two neuropeptide Y (NPY)-like
exocrine conopeptides, identified in the venom of Conus
betulinus. NPY (YPSKPDNPGEDAPAEDLARYYSALR
HYINLITRQRYa with a: N-terminal amidation) is an endo-
crine neurotransmitter found in the brain and autonomic
nervous system of both vertebrates and invertebrates. It is
Table 11 Characteristics of conolysins. Their amino acid sequences, respective species, targets and references are indicated
Peptide Amino acid sequence Species Target Source
Conolysin-Mt1 FHPSLWVLIPQYIQLIRKILKSG C. mustelinus cellular membranes [61]
Conolysin-Mt2 FHPSLWVLIPQYIQLIRKILKSa C. mustelinus cellular membranes [61]
aC-terminal amidation
Table 12 Characteristics of cono-NPYs. Their amino acid sequences, respective species and references are indicated
Peptide Amino acid sequence Species Target Source
Cono-NPY TVSDPPARPAVFHSREELMNYVRELNRYFAIVGRPRYa C. betulinus ? [62]
Cono-NPF TVSDPPARPAVFHSREELMNYVRELNRYFAIVGRPRFa C. betulinus ? [66]
aN-terminal amidation
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associated with a number of biological functions, such as
feeding behavior, energy balance, blood pressure, circa-
dian rhythms, sexual behavior, memory processing, cog-
nition, anxiety and epilepsy [63–65] Several NPY
receptors have been identified in mammals and all of
them are G-protein coupled receptors (GPCRs).
Pharmacological properties of cono-NPYs
The bioactivities of cono-NPYs (Table 12) were assayed
by intraventricular injection of these peptides into mice
brain. At a dose of 20 μg/mouse, the mice showed signs
of hyperactivity, such as jumping, rapid circling, and tail
flicking. The symptoms appeared 20 s after injection and
lasted for 40–60 s. Then, the mice calmed down and
recovered. Despite these biological activities, it remains
to be clarified if their real receptors are NPY receptors
or related GPCRs [62].
Other hormone-like conopeptides
Recently, two new hormone-like conopeptides, elevenin-
Vc1 and PH4-Vc1 (prohormone-4), were described by
Robinson et al. [66] (Table 13). C. victoriae elevenin was
identified as a 19 amino acid mature peptide with one pair
of cysteines. Other elevenin transcripts have been identi-
fied in gastropod mollusks and annelids. Prohormone-4
precursors were identified in the venom gland transcrip-
tomes of several other species of Conus (C. geographus,
C. tessulatus, C. varius and C. virgo). In honey bee,
prohormone-4 was identified in the brain and has been
implicated in the regulation of behavior [66].
Both conopeptides are part of the injected venom
cocktail of C. victoriae, unambiguously demonstrating
their role in envenomation. These and several other previ-
ously reported venom components (insulin, thyrostimulin,
conopressin, conoCAPs, conomap) seem to be recruited
into the venom from endogenous processes. Up to now,
the molecular targets of both elevenin and prohormone-4
remain to be determined.
Conclusion
Conus venoms contain a remarkable diversity of pharma-
cologically active small peptides. Of this venom cocktail,
disulfide-poor conotoxins are mostly minor components.
Moreover, an even smaller portion has only one disulfide
bond, which makes cysteine-poor conopeptides less in-
vestigated than its cysteine-rich equivalents. This review
provides an overview of 12 families of disulfide-poor
peptides. As such, a description of the chemical features,
pharmacological properties and the biological role of the
venom components is given. Nevertheless, numerous
Table 13 Characteristics of two hormone-like conopeptides. Their amino acid sequences, respective species and references are indicated
Peptide Amino acid sequence Species Target Source
Elevenin-Vc1 RRIDCKVFVFAPICRGVAA C. victoriae ? [66]
Prohormone-4-Vc1 IGFPGFSTPPR C. victoriae ? [66]
Table 14 Overview of the different families of disulfide-poor conopeptides discussed in this review. The different conopeptide
families, a representative peptide and amino acid sequence of this peptide, respective Conus species, targets and, when applicable,
clinical applications are indicated
Family Peptide
representative
Sequence Conus species Target Clinical applications
Conopressin Lys-conopressin-G CFIRNCPKGa C. geographus Vasopressin receptor Cardiovascular/mood
Contryphan Contryphan-R GCOWEPWCa C. radiatus VGPC, VGCC
ConoCAP ConoCAP-a PFCNSFGCYNa C. villipinii ?
ConoGAY ConoGAY-AusB GAYFDGFDVPCVPRRDDC C. australis ?
Conantokin Con-G GEγγLQγNQγLIRγKSNa C. geographus NMDA receptor Pain/epilepsy
Contulakin Cont-G ZSEEGGSNAT#KKPYIL C. geographus Neurotensin Receptor Pain
Conorfamides Conorfamide-Sr1 GPMGWVPVFYRFa C. spurius RFamide receptor?
Conophan Conophan Gld-V AOANSVWS C. gladiator ?
Conomaps Conp-Vt AFVKGSAQRVAHGYa C. vitelinus ?[Excitatory peptide]
Conomarphin Conomarphin DWEYHAHPKONSFWT C. marmoreus ?
Conolysin Conolysin-Mt2 FHPSLWVLIPQYIQLIRKILKSa C. mustelinus Cellular membranes
Cono-NPY Cono-NPY TVSDPPARPAVFHSREELMNYVRELNRYFAIVGRPRYa C. betulinus ?
Hormone-like
conopeptides
Elevenin
PH-4
RRIDCKVFVFAPICRGVAA
IGFPGFSTPPR
C. victoriae ?
aN-terminal amidation; W: D -tryptophan; γ = Gla: γ-carboxyglutamic acid; Z = pE: pyroglutamaat; T#: Gal-GalNAc-Thr; V: D -Valine; F: D -Phe
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questions still need to be answered. These include the
determination of specific targets or mechanisms of
action and their biological role in the venom that still
remains to be elucidated and, on the other hand, the lack
of structure-activity data.
From the limited number of disulfide-poor conopep-
tides characterized up to now, two (contulakin-G and
conantokin-G) have already reached clinical trials, which
indicates Conus venoms as promising compounds for
drug discovery. Since disulfide-poor conotoxins do not
suffer from folding problems encountered with multiple
disulfide bridges, they are interesting scaffolds for drug
discovery. Moreover, cyclic structures – such as cono-
pressin, contryphans and conoGAYs – are remarkable
compounds when it comes to bioavailability. It has
namely been proven that cyclic structures are more
stable and less sensitive to proteolysis [67]. Therefore,
we are hopeful that these peptides will get more attention
in future research. A final overview of the different fam-
ilies of disulfide-poor conopeptides is given in Table 14.
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